Prostate cancer: Radiopharmaceuticals. Part 2 - PSMA theranostics

December 06, 2023 00:21:48
Prostate cancer: Radiopharmaceuticals. Part 2 - PSMA theranostics
COR2ED - Oncology Medical Conversation
Prostate cancer: Radiopharmaceuticals. Part 2 - PSMA theranostics

Dec 06 2023 | 00:21:48

/

Show Notes

Dr. Tanya Dorff (City of Hope Comprehensive Cancer Center, Los Angeles, USA) and Dr. Phillip Koo (Banner MD Anderson Cancer Center, Arizona, USA) discuss the latest developments in the field of radiopharmaceuticals and their use in Prostate Cancer.

This second episode focuses on PSMA-targeted radiopharmaceuticals and how PSMA can be a target for imaging as well as for therapies. Efficacy and safety data from the phase 2 TheraP study are discussed which investigated lutetium-PSMA versus cabazitaxel in patients with mCRPC who had progressed on docetaxel. The experts also discuss the ongoing VISION trial and what the results may mean for clinical practice as well as other ongoing trials looking at lutetium-PSMA in combination with other prostate cancer therapies such as PARP inhibitors, immunotherapies, hormonal therapies and chemotherapy. Treatment sequencing is also considered in terms of where lutetium-PSMA fits into clinical practice for mCRPC patients and how the treatment compares to Radium-223.

Other Episodes

Episode

April 25, 2024 00:27:48
Episode Cover

Cáncer de pulmón: dificultades en la fase preanalítica y pruebas de biomarcadores

¿Cuáles son los desafíos frecuentes en la fase preanalítica del cáncer de pulmón, y cómo podemos superarlos? ¿Por qué es importante identificar las alteraciones...

Listen

Episode

December 06, 2023 00:20:49
Episode Cover

RCC: Treating advanced RCC - The role of VEGFR-TKIs alone or in combination therapy

Prof. Thomas Powles, a Medical Oncologist from Barts Cancer Centre in the UK and Prof. Georg Hutterer, a Urologist from the Medical University of...

Listen

Episode

November 25, 2024 00:23:25
Episode Cover

Testing to treatment of BRAF-mutant metastatic NSCLC

 Testing to treatment of BRAF-mutant metastatic NSCLC    In this educational podcast episode, experts Prof. David Planchard and Dr Federico Cappuzzo discuss the significance of...

Listen